Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency

@article{Matveeva2015OncolysisBP,
  title={Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency},
  author={Olga V. Matveeva and Zong Sheng Guo and Svetlana A. Shabalina and Peter M. Chumakov},
  journal={Molecular Therapy Oncolytics},
  year={2015},
  volume={2}
}
Oncolytic paramyxoviruses include some strains of Measles, Mumps, Newcastle disease, and Sendai viruses. All these viruses are well equipped for promoting highly specific and efficient malignant cell death, which can be direct and/or immuno-mediated. A number of proteins that serve as natural receptors for oncolytic paramyxoviruses are frequently overexpressed in malignant cells. Therefore, the preferential interaction of paramyxoviruses with malignant cells rather than with normal cells is… 
Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies
TLDR
Preclinical studies and phases I–III of clinical trials yield very encouraging results and warrant continued research of oncolytic paramyxoviruses as a particularly valuable addition to the existing panel of cancer-fighting approaches.
Oncolysis by paramyxoviruses: preclinical and clinical studies
TLDR
In general, preclinical studies and phase 1–3 clinical trials yield very encouraging results and warrant continued research of oncolytic paramyxoviruses as a particularly valuable addition to the existing panel of cancer-fighting approaches.
Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy
TLDR
The induction of autophagy has been revealed to enhance the immunogenicity of tumor cells via the release of damage-associated molecular patterns (DAMPs) and the activation of Autophagy-related immunogenic cell death (ICD).
Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy
TLDR
The prospects for using paramyxovirus receptors as biomarkers for successful personalized virotherapy for certain types of cancer and a combination of expression signatures of immune and receptor genes could be used to find a set of oncolytic viruses that are more effective for specific malignancies.
Fusogenic Viruses in Oncolytic Immunotherapy
TLDR
The potential of fusogenic oncolytic viruses as optimal candidates to enhance immunotherapy and initiate broad antitumor responses is discussed, and growing evidence indicates that fusogenicity could be an important feature to consider in the design of optimal onColytic virus platforms for combinatorial on colytic immunotherapy.
Oncolytic effect of Newcastle Disease Virus is attributed to interferon regulation in canine mammary cancer cell lines.
TLDR
This is the first description of oncolysis by an NDV strain in canine mammary cancer cells, and specific molecular pathways related to NDV susceptibility in these cancer cells are demonstrated, opening the possibility to use NDV as a therapeutic-targeted option for more malignant CMCs.
Biochemical variations in cytolytic activity of ortho- and paramyxoviruses in human lung tumor cell culture
  • O. Zhirnov
  • Biology, Medicine
    Biochemistry (Moscow)
  • 2017
TLDR
An optimal strategy for oncolytic virus-mediated destruction of tumor cells in cancer patients requires selection of the most appropriate oncoleytic virus based on the mechanism of its cytolytic action in a particular type of tumor.
Could Oncolytic Viruses Provide a Breakthrough in Oncology?
  • P. Chumakov
  • Medicine, Biology
    Herald of the Russian Academy of Sciences
  • 2019
TLDR
To incorporate viral cancer therapy into mainstream medical practice, it is necessary to intensify basic research on viral oncolysis mechanisms, to develop new therapeutic viral strains and tests for their personalized selection, and to improve methods of the local and systemic delivery of on colytic viruses to tumor locations.
Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines
TLDR
It is shown that a non-pathogenic strain of coxsackievirus B6 (LEV15) can efficiently replicate to high titers in the malignant human cell lines C33A, DU145, AsPC-1 and SK-Mel28, although it displays much lower replication efficiency in A431 and A549 cells and very limited replication ability in RD and MCF7 cells.
Oncolytic Viruses in Tumor Therapy: The Russian Perspective
TLDR
Biotechnological advances in the development of therapeutic applications of OVs in Russia are discussed, with particular emphasis on the OV-mediated treatment of glioblastoma.
...
1
2
3
4
...

References

SHOWING 1-10 OF 175 REFERENCES
Oncolytic enteroviruses
TLDR
This review focuses on the main members of the Enterovirus genus, such as ECHO, coxsackievirus, and vaccine strains of poliovirus as a promising source for the development of oncolytic agents applicable for cancer therapy.
Oncolytic poxviruses
Modern data on selection and design of poxviruses, which are able to specifically lyse tumor cells of various origins and induce antitumor immunity and apoptosis of malignant cells, are presented in
Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells
TLDR
It is demonstrated that NDV possesses oncolytic activity in tumor cells capable of a robust type I interferon (IFN) response, suggesting that another mechanism underlies NDV's tumor specificity.
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.
TLDR
It is demonstrated that modulation of innate immune responses by NDV results in enhancement of its oncolytic properties and warrant further investigation of this strategy in design of on colytic NDV vectors against human tumors.
Vesicular stomatitis virus as an oncolytic vector.
TLDR
The data and others demonstrate that VSV as well as other RNA viruses could provide a promising and exciting approach to cancer therapy and could increase a tumor's susceptibility to chemotherapeutic agents and/ or importantly, the host immune response.
Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.
TLDR
It is found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation, indicating that rSeV could be a powerful immune booster for DC-based cancer immunotherapy that is worth investigating further.
Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer
TLDR
Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they are made commercially available, and commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents.
Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer
TLDR
The modular nature of gene transcription, the undetectable rate of recombination, and the lack of a DNA phase in the replication cycle make NDV a suitable candidate for the rational design of a safe and stable vaccine and gene therapy vector.
Attenuated and Protease-Profile Modified Sendai Virus Vectors as a New Tool for Virotherapy of Solid Tumors
TLDR
Novel tumor-selective oncolytic rSeV vectors are successfully developed, constituting a new tool for virotherapy of solid tumors being ready for further preclinical and clinical development to address distinct tumor types.
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
TLDR
Potential combination strategies to target cells into specific modes of ICD and enhance cancer immunogenicity, including blockade of immune checkpoints, in order to break immune tolerance, improve antitumor immunity, and thus the overall therapeutic efficacy are discussed.
...
1
2
3
4
5
...